EXHIBIT 99.01
| Hampshire International Business Park Chineham Basingstoke Hampshire RG24 8EP United Kingdom Tel +44 (0)1256 894000 Fax +44 (0)1256 894708 www.shire.com |  |
Press Release
STOCK EXCHANGE ANNOUNCEMENT
28 June 2005
Shire Pharmaceuticals Group plc (the “Company”)
The Company announces that it was notified on 28 June 2005 under Sections 198 to 203 of the Companies Act that, at close of business on 23 June 2005, The Goldman Sachs Group, Inc., was interested in 18,053,954 ordinary shares of £0.05p each in the capital of the Company. This holding represents 3.6655 per cent of the issued ordinary share capital of the Company.
T May
Company Secretary
For further information please contact:
| Investor Relations | Cléa Rosenfeld (Rest of the World) | + | 44 1256 894 160 |
| Brian Piper (North America) | + | 1 484 595 8252 |
Notes to editors
Shire Pharmaceuticals Group plc
Shire Pharmaceuticals Group plc (Shire) is a global specialty pharmaceutical company with a strategic focus on meeting the needs of the specialist physician and currently focuses on developing projects and marketing products in the areas of central nervous system (CNS), gastrointestinal (GI), and renal diseases. Shire has operations in the world’s key pharmaceutical markets (US, Canada, UK, France, Italy, Spain and Germany) as well as a specialist drug delivery unit in the US.
For further information on Shire, please visit the Company’s website:www.shire.com.
Registered in England 2883758 Registered Office as above